Selected article for: "dose treatment and single dose treatment"
Author: Salvador, Fernando; Lucas-Dato, Ana; Roure, Silvia; Arsuaga, Marta; Pérez-Jacoiste, Asunción; García-Rodríguez, Magdalena; Pérez-Molina, José A.; Buonfrate, Dora; Saugar, José María; Molina, Israel
Title: Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
  • Cord-id: 2j26tsf2
  • Document date: 2021_6_27
    • ID: 2j26tsf2
    Snippet: Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary
    Document: Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and active transmission: 1, 2
    • abdominal pain and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • absolute number and lymphocyte count: 1, 2, 3
    • action mechanism and liver disease: 1, 2, 3, 4
    • action mechanism and lymphocyte count: 1, 2
    • active screening and liver disease: 1
    • liver disease and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8
    • liver profile and lymphocyte count: 1